Is EPS15 p.Ala2Ser (c.4G>T) pathogenic?

EPS15 p.Ala2Ser (c.4G>T) is classified Uncertain significance in EPS15 (ClinVar, Single submitter, 1 submitter; last evaluated 2025-09-11). AlphaMissense: likely benign (0.1681); Rare (popmax 0.818%, afr).

How common is EPS15 p.Ala2Ser (c.4G>T) in the general population?

EPS15 p.Ala2Ser (c.4G>T) is rare (popmax 0.818%, afr) (gnomAD).

What do computational predictors say about EPS15 p.Ala2Ser (c.4G>T)?

AlphaMissense predicts likely benign (score 0.1681) — an in-silico prediction, not a clinical call.

EPS15 p.Ala2Ser

c.4G>T · VCV4250216

Uncertain significance Single submitter

Classification

Uncertain significance

ClinVar

Review

Single submitter ★☆☆☆

ClinVar · 1 submitter

AlphaMissense

likely benign

0.1681 · ACMG-weighted

gnomAD v4.1

Rare

rare (popmax 0.818%, afr)

Missense predictors

0/3 damaging

AlphaMissense, REVEL, SaProt

Computational evidence

Protein change
AlphaMissense	0.1681	likely benign
REVEL	0.045	moderately benign-leaning
SaProt	LLR -7.94	tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 7	GERP 0.43, phastCons 1
Regional constraint	o/e 1.00	unconstrained · MANE · 163 kb · p 0.94 · regional, not allelic
Overall
CADD	22.9	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.818% African / African-American · 552/67,460 alleles

Filtering AF 0.762% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.739%

Overall 0.044% 613/1,391,648 alleles · rare

Ancestry group	Frequency	1 in
African / African-Americangrpmax	0.818%	122
Remaining individualsnot grpmax-eligible	0.0671%	1,490
Admixed American	0.0463%	2,162
Middle Eastern	0.021%	4,770
European (non-Finnish)	0.000755%	132,407

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: EPS15
Protein: p.Ala2Ser
Coding: c.4G>T
MANE Select: NM_001981
Type: single nucleotide variant
Location: chr1:51519228 (GRCh38)
Gene constraint: LOEUF 0.849 · pLI <0.01 (gnomAD)
Structure: AlphaFold pLDDT 67.60 · 13 PDB
Residue 2: the 'interaction with dab2' region; a modified residue (n-acetylalanine)

Full EPS15 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

EPS15 p.Ala208Ser Uncertain significance ★ ⚠ same type
EPS15 p.Ala39Thr Uncertain significance ★ ⚠ same type
EPS15 p.Ala423Val Uncertain significance ★ ⚠ same type
EPS15 p.Ala4Thr Uncertain significance ★ ⚠ same type
EPS15 p.Ala560Ser Uncertain significance ★ ⚠ same type
EPS15 p.Ala613Gly Uncertain significance ★ ⚠ same type
EPS15 p.Ala667Thr Uncertain significance ★ ⚠ same type
EPS15 p.Ala676Val Uncertain significance ★ ⚠ same type

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/eps15-p-ala2ser (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown